Stay updated on Tezepelumab in Chronic Urticaria Clinical Trial

Sign up to get notified when there's something new on the Tezepelumab in Chronic Urticaria Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tezepelumab in Chronic Urticaria Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    An NIH-wide notice about updates to terminology for artificial intelligence appears above the page’s 403 error.
    Difference
    1%
    Check dated 2026-10-24T19:25:01.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The site footer revision number changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T19:27:34.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site revision identifier changes from v3.7.0 to v3.7.1, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T19:52:23.000Z thumbnail image
  4. Check
    36 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error screen, indicating the record is inaccessible, while the surrounding site chrome remains visible.
    Difference
    20%
    Check dated 2026-09-19T18:30:16.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    The page revision has been updated from v3.6.5 to v3.6.6, indicating a minor platform update.
    Difference
    0.0%
    Check dated 2026-08-29T19:17:52.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    The page shows a new revision number (v3.6.5) replacing the previous version, signaling a post-publication update to the study page.
    Difference
    0.0%
    Check dated 2026-08-08T14:55:40.000Z thumbnail image

Stay in the know with updates to Tezepelumab in Chronic Urticaria Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tezepelumab in Chronic Urticaria Clinical Trial page.